Avugane^TM comprises a new, proprietary formulation of the HDAC inhibitor VPA with the potential for use as a topical treatment of inflammatory skin diseases, including acne vulgaris (common acne), psoriasis and atopic dermatitis. Promising data from a double-blind, randomised Phase II study of acne vulgaris patients was reported in April 2006, with Avugane^TM showing comparable efficacy and advantageous tolerability compared to a standard, marketed retinoid therapy. TopoTarget has initiated a double-blind randomised, placebo-controlled clinical Phase II study in acne vulgaris to further investigate the clinical utility of Avugane^TM. If successful, TopoTarget may consider conducting trials in psoriasis and atopic dermatitis.

Various patents, both granted and pending claiming:

Use of VPA in cancers including skin cancer

Combinations of VPA and radiation/drugs

The use of topically applied VPA for inflammatory skin diseases

A gel formulation of VPA for topical application

The use of VPA in acne

Available for out-licensing to a company with experience in the development and commercialisation of dermatology products